S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
Is Gold Really Boring? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
Is Gold Really Boring? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
Is Gold Really Boring? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
Is Gold Really Boring? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
NASDAQ:ARWR

Arrowhead Pharmaceuticals (ARWR) Stock Forecast, Price & News

$27.01
-0.22 (-0.81%)
(As of 09/20/2023 ET)
Compare
Today's Range
$26.89
$27.49
50-Day Range
$26.84
$36.08
52-Week Range
$23.09
$42.48
Volume
897,402 shs
Average Volume
928,476 shs
Market Capitalization
$2.90 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$54.53

Arrowhead Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.69 Rating Score
Upside/​Downside
101.9% Upside
$54.53 Price Target
Short Interest
Bearish
6.25% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.55
Upright™ Environmental Score
News Sentiment
0.48mentions of Arrowhead Pharmaceuticals in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$2.59 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.67) to ($2.65) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

374th out of 962 stocks

Pharmaceutical Preparations Industry

168th out of 448 stocks


ARWR stock logo

About Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

ARWR Price History

ARWR Stock News Headlines

Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Chardan Capital Keeps Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
ARWR - Arrowhead Pharmaceuticals, Inc.
Arrowhead: Biotech Innovation On Display
See More Headlines
Receive ARWR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARWR Company Calendar

Last Earnings
8/07/2023
Today
9/21/2023
Fiscal Year End
9/30/2023
Next Earnings (Estimated)
11/27/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARWR
Employees
397
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$54.53
High Stock Price Forecast
$90.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+101.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.69
Research Coverage
16 Analysts

Profitability

Net Income
$-176,060,000.00
Pretax Margin
-70.12%

Debt

Sales & Book Value

Annual Sales
$243.23 million
Book Value
$3.95 per share

Miscellaneous

Free Float
101,833,000
Market Cap
$2.90 billion
Optionable
Optionable
Beta
1.00

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Christopher R. Anzalone Ph.D. (Age 54)
    CEO, Pres & Director
    Comp: $1.65M
  • Mr. Kenneth A. MyszkowskiMr. Kenneth A. Myszkowski (Age 57)
    Chief Financial Officer
    Comp: $761.55k
  • Mr. Patrick O'Brien J.D. (Age 59)
    PharmD, COO, Gen. Counsel & Sec.
    Comp: $749.86k
  • Dr. James C. Hamilton M.D. (Age 45)
    MBA, Chief of Discovery & Translational Medicine
    Comp: $676.81k
  • Ms. Tracie Oliver
    Chief Commercial Officer
  • Dr. Mark M. Davis Ph.D.
    Founder and Founder & Director of Insert Therapeutics Inc & Calando
  • Dr. Vincent Anzalone CFA
    Head of Investor Relations & VP
  • Mr. Howard Lovy
    Director of Communications
  • Dr. Mark Seefeld (Age 69)
    Head of Toxicology & VP
  • Dr. Javier San Martin M.D. (Age 58)
    Chief Medical Officer













ARWR Stock - Frequently Asked Questions

Should I buy or sell Arrowhead Pharmaceuticals stock right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last twelve months. There are currently 5 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ARWR shares.
View ARWR analyst ratings
or view top-rated stocks.

What is Arrowhead Pharmaceuticals' stock price forecast for 2023?

16 analysts have issued 1 year price targets for Arrowhead Pharmaceuticals' stock. Their ARWR share price forecasts range from $27.00 to $90.00. On average, they expect the company's share price to reach $54.53 in the next year. This suggests a possible upside of 101.9% from the stock's current price.
View analysts price targets for ARWR
or view top-rated stocks among Wall Street analysts.

How have ARWR shares performed in 2023?

Arrowhead Pharmaceuticals' stock was trading at $40.56 at the beginning of 2023. Since then, ARWR shares have decreased by 33.4% and is now trading at $27.01.
View the best growth stocks for 2023 here
.

When is Arrowhead Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 27th 2023.
View our ARWR earnings forecast
.

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released its earnings results on Monday, August, 7th. The biotechnology company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.58) by $0.38. The biotechnology company earned $15.83 million during the quarter, compared to analysts' expectations of $45.42 million. Arrowhead Pharmaceuticals had a negative trailing twelve-month return on equity of 42.79% and a negative net margin of 69.38%. The company's revenue was down 51.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.68) earnings per share.

What other stocks do shareholders of Arrowhead Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), Salesforce (CRM) and Advanced Micro Devices (AMD).

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Who are Arrowhead Pharmaceuticals' major shareholders?

Arrowhead Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (11.95%), State Street Corp (5.14%), JPMorgan Chase & Co. (2.69%), Geode Capital Management LLC (2.01%), Credit Suisse AG (1.33%) and Northern Trust Corp (1.21%). Insiders that own company stock include Adeoye Y Olukotun, Backer Marianne De, Christopher Richard Anzalone, Douglas B Given, Douglas B Given, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Mauro Ferrari, Patrick O'brien, Tracie Oliver and William D Waddill.
View institutional ownership trends
.

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arrowhead Pharmaceuticals' stock price today?

One share of ARWR stock can currently be purchased for approximately $27.01.

How much money does Arrowhead Pharmaceuticals make?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) has a market capitalization of $2.90 billion and generates $243.23 million in revenue each year. The biotechnology company earns $-176,060,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

How many employees does Arrowhead Pharmaceuticals have?

The company employs 397 workers across the globe.

How can I contact Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The official website for the company is www.arrowheadpharma.com. The biotechnology company can be reached via phone at (626) 304-3400, via email at ir@arrowheadpharma.com, or via fax at 626-304-3401.

This page (NASDAQ:ARWR) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -